gdc
PSSGuide_2021
Leukemia

Drugs for Leukemia

Find financial assistance programs available for leukemia drugs.
Acute Lymphoblastic Leukemia (ALL)

Arranon (nelarabine)

Drug company: Novartis
800-245-5356

Arranon is a nucleoside metabolic inhibitor used for the treatment of patients with T-cell acute lymphoblastic leukemia (ALL).

Novartis Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Arranon:

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Arranon for free until prescription drug coverage becomes available to them.

Besponsa (inotuzumab ozogamicin) for Injection

Drug company: Pfizer
877-744-5675

Besponsa is a CD22-directed antibody-drug conjugate used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Pfizer Oncology Together offers 1 financial assistance program for patients using Besponsa:

Pfizer Patient Assistance Program

This program provides Besponsa free, or at a savings, for eligible patients with no healthcare coverage, as well as for patients with government insurance (who have no available independent charitable foundation support).

Blincyto (blinatumomab)

Drug company: Amgen
888-427-7478

Blincyto is a bispecific CD19-directed CD3 T-cell engager used for the treatment of patients with B-cell precursor acute lymphoblastic leukemia (ALL) that is in first or second remission, with minimal residual disease. Blincyto is also used for the treatment of patients with relapsed or refractory B-cell precursor ALL.

Amgen Assist 360 offers 3 financial assistance programs for patients using Blincyto:

Amgen FIRST STEP Program

With this program, eligible patients with private insurance will pay $0 for the first dose of Blincyto and $5 for each subsequent dose, with a maximum annual benefit of $10,000.

Amgen Assist 360

Enrolling in this program gives patients drug reimbursement assistance, as well as referrals for transportation, lodging, and copay assistance. For patients with Medicare or Medicaid, Amgen Assist 360 provides referrals to independent nonprofit foundations that can help pay for the medication.

Amgen Safety Net Foundation

Qualifying, uninsured patients can receive Blincyto for free through Amgen’s nonprofit patient assistance program.

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used, in combination with chemotherapy, for the treatment of adults with relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) and pediatric patients with Ph+ ALL.

Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:

Novartis Oncology Universal Co-Pay Program

Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum annual benefit of $30,000.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Gleevec for free until prescription drug coverage becomes available to them.

Iclusig (ponatinib)

Drug company: Takeda Oncology
844-817-6468

Iclusig is a kinase inhibitor used for the treatment of adults with Ph+ acute lymphoblastic leukemia (ALL) for whom no other tyrosine kinase inhibitor therapy is indicated. Iclusig is also used for adults with Ph+ ALL and T315I mutation.

Takeda Oncology offers 2 financial assistance programs for patients using Iclusig:

Takeda Oncology Co-Pay Assistance Program

Eligible patients with private insurance will pay only a $10 per month copay or co-insurance for Iclusig. This program covers monthly out-of-pocket expenses of more than $10 per prescription, up to a maximum annual benefit of $25,000.

Takeda Oncology Patient Assistance Program

Through this program, eligible patients who are uninsured or underinsured may receive a monthly supply of Iclusig at no cost. Qualified patients may be enrolled in this program for up to 1 year.

Kymriah (tisagenlecleucel)

Drug company: Novartis
844-459-6742

Kymriah is a CD19-directed genetically modified CAR T-cell immunotherapy used for the treatment of young patients (up to age 25) with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

Novartis Patient Assistance NOW offers 1 financial assistance program for patients using Kymriah:

Kymriah Cares

This program offers financial assistance to eligible patients to help them access Kymriah. Patients must meet program eligibility criteria to qualify for support. Patients should work with their treatment center to submit a Service Request Form for Patient Support to Kymriah Cares.

Marqibo (vincristine sulfate liposome)

Drug company: Acrotech Biopharma
888-537-8277

Marqibo is a vinca alkaloid used for the treatment of adult patients with Ph-negative acute lymphoblastic leukemia (ALL).

Acrotech Biopharma, through its Specialty Therapy Access Resources (STAR) program, offers 2 financial assistance programs for patients who are prescribed Marqibo:

STAR Co-Pay Assistance

Eligible, privately insured patients will pay $0 for the first injection of Marqibo and then $25 for each subsequent injection, with a maximum benefit of up to $10,000 annually.

STAR Patient Assistance Program

This program provides Marqibo free of charge to enrolled patients who meet the income, insurance, and residency eligibility criteria.

Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) Injection

Drug company: Jazz Pharmaceuticals
833-533-5299

Rylaze is an asparagine-specific enzyme approved, as part of a multiagent chemotherapy regimen, for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma in patients aged 1 month or older who have hypersensitivity to E. coli-derived asparaginase.

JazzCares offers 2 financial assistance programs for patients using Rylaze:

JazzCares Copay Savings Card

With this program, eligible, commercially insured patients may pay as little as $10 for Rylaze, subject to an annual maximum benefit.

JazzCares Patient Assistance Program

Uninsured or underinsured patients who meet certain financial requirements may be able to receive Rylaze at no cost.

Sprycel (dasatinib)

Drug company: Bristol Myers Squibb
800-861-0048

Sprycel is a kinase inhibitor used for the treatment of patients with Ph+ acute lymphoblastic leukemia (ALL).

Bristol Myers Squibb Access Support offers 3 financial assistance programs for patients using Sprycel:

Co-Pay Assistance Program

Eligible patients may pay as little as $0 per 30-day supply of Sprycel, up to a maximum of $15,000 per calendar year.

Sprycel 30-Day Trial Offer

New patients may be eligible for a free 30-day trial offer of Sprycel.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Sprycel may be eligible for help paying for their medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Tecartus (brexucabtagene autoleucel)

Drug company: Kite Pharma
844-454-5483

Tecartus is a CAR T-cell therapy (gene therapy) used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Kite Pharma offers 1 financial assistance program for patients who have been prescribed Tecartus:

Kite Konnect

This program helps patients and healthcare teams throughout treatment with Tecartus. (For more information call 844-454-5483.)

Acute Myeloid Leukemia (AML)

Daurismo (glasdegib) Tablets

Drug company: Pfizer
877-744-5675

Daurismo is a hedgehog pathway inhibitor used, in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults age 75 years or older, and in patients whose comorbidities prevent them from using intensive induction chemotherapy.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Daurismo:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible, privately insured patients with their monthly copay for Daurismo, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Daurismo for free or at a savings. Eligible patients who have government insurance may also receive Daurismo for free if they cannot find financial support from an independent charitable foundation.

Idamycin PFS (idarubicin hydrochloride)

Drug company: Pfizer
877-744-5675

Idamycin PFS is a sterile, semi-synthetic antineoplastic anthracycline used, in combination with other approved antileukemic drugs, for the treatment of patients with acute myeloid leukemia (AML).

Pfizer Oncology Together offers 1 financial assistance program for patients using Idamycin PFS:

Pfizer RxPathways

Patients who are prescribed a Pfizer specialty medicine, such as Idamycin PFS, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Idhifa (enasidenib) Tablets

Drug company: Bristol Myers Squibb
800-861-0048

Idhifa is an IDH2 inhibitor used for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Idhifa:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductible, copay, or co-insurance costs for eligible patients with private insurance who have been prescribed Idhifa. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Idhifa, may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Mylotarg (gemtuzumab ozogamicin) for Injection

Drug company: Pfizer
877-744-5675

Mylotarg is a CD33-directed antibody-drug conjugate used for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults, and relapsed or refractory CD33-positive AML in patients age 2 years or older.

Pfizer Oncology Together offers 1 financial assistance program for patients using Mylotarg:

Pfizer Patient Assistance Program

Eligible patients who do not have insurance and are unable to afford Mylotarg may receive their medicine for free or at a savings through this program.

Onureg (azacitidine) Tablets

Drug company: Bristol Myers Squibb
800-861-0048

Onureg is a nucleoside metabolic inhibitor used for continued treatment of patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery after intensive induction chemotherapy and who cannot complete intensive curative therapy.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients who have been prescribed Onureg:

BMS Oncology Co-Pay Assistance Program

Through this program, eligible patients who have private insurance may pay as little as $10 per 30-day supply of Onureg, with a maximum benefit limit of $15,000 per calendar year.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Eligible patients who are uninsured or underinsured may be able to receive Onureg for free through this program. Patients must have a yearly income that is at or below 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Rydapt (midostaurin) Capsules

Drug company: Novartis
800-245-5356

Rydapt is a kinase inhibitor used, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for the treatment of adults with acute myeloid leukemia (AML) and FLT3 mutation.

Novartis Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Rydapt:

Novartis Oncology Universal Co-pay Program

For eligible patients with private insurance, this copay program ensures a prescription copay of $10 per month for Rydapt. Novartis pays the remaining balance until the annual maximum of $15,000 is met.

Rydapt Now Access Program

For eligible patients with private insurance whose insurance coverage is delayed, this program provides a free 14-day supply of medication shipped directly to the patient’s home.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Rydapt for free until prescription drug coverage becomes available to them.

Tibsovo (ivosidenib) Tablets

Drug company: Servier Pharmaceuticals
844-409-1141

Tibsovo is an IDH1 inhibitor used for the treatment of adults aged 75 or older or those who have comorbidities that preclude the use of intensive induction chemotherapy who are newly diagnosed with acute myeloid leukemia (AML) and a susceptible IDH1 mutation, as detected by an FDA-approved test. Tibsovo is also used for the treatment of adults with relapsed (coming back) or refractory (not responding to therapy) AML that is associated with an IDH1 mutation.

Servier Pharmaceuticals offers 4 financial assistance programs for patients using Tibsovo:

Tibsovo Co-Pay Program

Qualified patients who have commercial or private insurance pay no more than a $25 copay per prescription of Tibsovo through this program, with a maximum annual benefit of $25,000.

Patient Assistance Program

Uninsured or underinsured patients who meet specified financial and eligibility requirements may qualify for assistance with Tibsovo through this program.

QuickStart Program

To be eligible for this program, patients must have commercial or private insurance coverage that has been delayed by 5 business days or more and meet the specified eligibility requirements.

Coverage Interruption Program

Patients must reside in the United States and must currently be taking Tibsovo, with at least 1 previous private insurance dispense.

Venclexta (venetoclax) Tablets

Drug company: AbbVie/Genentech
866-422-2377

Venclexta is a BCL-2 inhibitor used, in combination with azacitidine, decitabine, or low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients age 75 years or older, or in patients with AML whose comorbidities prevent them from using intensive induction chemotherapy.

AbbVie and Genentech offer 2 financial assistance programs for patients using Venclexta:

Genentech Oncology Co-pay Assistance Program

For privately insured patients, this program ensures a $5 copay for Venclexta, with up to a $25,000 benefit annually. This program has no income requirements.

Genentech Patient Foundation

This foundation provides Venclexta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Venclexta is also provided free for patients who are unable to afford their out-ofpocket costs and cannot find other financial assistance.

Vyxeos (daunorubicin + cytarabine) Liposome for Injection

Drug company: Jazz Pharmaceuticals
833-533-5299

Vyxeos is a liposomal combination of daunorubicin (an anthracycline topoisomerase inhibitor) and cytarabine (a nucleoside metabolic inhibitor) used for the treatment of adults and pediatric patients 1 year or older with newly diagnosed therapy-related acute myeloid leukemia (AML) or with AML and myelodysplasia-related changes.

JazzCares offers 2 financial assistance programs for patients who are prescribed Vyxeos:

JazzCares Copay Savings Card

Patients with private insurance may qualify for assistance with out-of-pocket costs for Vyxeos.

JazzCares Patient Assistance Program

This program offers Vyxeos at no cost for patients who are uninsured or do not have coverage for Vyxeos. Patients must have a total household gross income of less than 400% of the federal poverty level. The benefit is subject to an annual maximum.

Xospata (gilteritinib)

Drug company: Astellas
844-632-9272

Xospata is a kinase inhibitor used for the treatment of adults with relapsed or refractory acute myeloid leukemia and FLT3 mutation, as detected by an FDA-approved test.

Astellas offers 3 financial assistance programs for patients using Xospata:

Xospata Patient Savings Program

Eligible patients who have private insurance will pay as little as $0 per prescription of Xospata, with a maximum annual benefit of $25,000. This program has no income requirements.

Xospata Quick Start+ Program

This program provides a one-time, 7-day supply of Xospata at no cost to eligible patients who have private insurance and are experiencing an insurance-related delay in receiving their medication.

Astellas Patient Assistance Program

Through this program, patients who are uninsured or have insurance that excludes coverage for Xospata may qualify to receive their medication at no cost.

Zarxio (filgrastim-sndz)

Drug company: Sandoz
844-726-3691

Zarxio, a biosimilar to Neulasta, is a leukocyte growth factor used to reduce the time to neutrophil recovery and the duration of fever in patients with acute myeloid leukemia, after induction or consolidation chemotherapy treatment.

Sandoz One Source offers 1 financial assistance program for patients using Zarxio:

Sandoz One Source Commercial Co-Pay Program

Through this program, privately insured patients will pay $0 copay for the first dose of Zarxio and for subsequent doses, with a maximum benefit of $10,000 annually. There is no income eligibility requirement.

Chronic Lymphocytic Leukemia (CLL)

Arzerra (ofatumumab)

Drug company: Novartis
800-245-5356

Arzerra is a CD20-directed cytolytic monoclonal antibody used for the treatment of patients with chronic lymphocytic leukemia. In certain cases, Arzerra is used in combination with chlorambucil, or fludarabine and cyclophosphamide.

Novartis Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Arzerra:

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Arzerra for free until prescription drug coverage becomes available to them.

Bendeka (bendamustine HCl) Injection

Drug company: Teva
888-587-3263

Bendeka is an alkylating drug used for the treatment of patients with chronic lymphocytic leukemia.

Teva offers 1 financial assistance program for patients using Bendeka:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Bendeka for free.

Calquence (acalabrutinib) Capsules

Drug company: AstraZeneca
844-275-2360

Calquence is a Bruton tyrosine kinase inhibitor used for the treatment of adults with chronic lymphocytic leukemia.

AstraZeneca 360 offers 2 financial assistance programs for patients who are using Calquence:

Calquence Co-pay Savings Program

Eligible patients who have private insurance will pay $0 per month and may have access to up to $26,000 annually to assist with the out-of-pocket prescription costs associated with Calquence.

AZ&Me Prescription Savings Program

This program offers free medication from AstraZeneca to qualifying patients without insurance, those in Medicare Part D, and those who receive their medication through participating healthcare facilities.

Copiktra (duvelisib)

Drug company: Secura Bio
833-570-2273

Copiktra is a dual PI3 kinase inhibitor used for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia, after at least 2 other therapies.

Secura Bio, through Secura Care, offers 3 financial assistance programs for patients using Copiktra:

Verastem Cares Co-Pay Assistance

Patients who have private insurance may pay as little as $5 for their prescription of Copiktra, with a maximum annual benefit of $25,000. This program has no patient income requirement.

Co-Pay Program

Eligible patients who have commercial or private insurance pay no more than $5 per month for Copiktra, up to an annual maximum of $25,000 per calendar year.

Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Copiktra at no cost through this program, upon qualification.

Secura Bio Quickstart Program

Through this program, patients who have a delay of 5 days or more in obtaining prior authorization can receive the first cycle of Copiktra at no cost.

Gazyva (obinutuzumab)

Drug company: Genentech
866-422-2377

Gazyva is a CD20-directed cytolytic antibody used, in combination with chlorambucil, for the treatment of patients with untreated chronic lymphocytic leukemia (CLL). Gazyva is also used, in combination with Imbruvica or with Venclexta, for the first-line treatment of patients with CLL.

Genentech Oncology offers 2 financial assistance programs for patients using Gazyva:

Genentech Oncology Co-pay Assistance Program

The program ensures a $5 copay for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Gazyva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Gazyva is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Imbruvica (ibrutinib) Capsules/Tablets

Drug company: Pharmacyclics
888-968-7743

Imbruvica is a Bruton tyrosine kinase inhibitor used for the first-line treatment of patients with chronic lymphocytic leukemia (CLL), with or without 17p deletion. Imbruvica is also used, in combination with Gazyva, for the first-line treatment of patients with CLL.

Pharmacyclics’ You&i Support Program offers 2 financial assistance programs for patients using Imbruvica:

Imbruvica Copay Card

Patients with commercial or private insurance will pay as little as $10 monthly for Imbruvica, with a maximum annual program benefit of $24,600. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.

Johnson & Johnson Patient Assistance Foundation

This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.

Rituxan (rituximab)

Drug company: Genentech
866-422-2377

Rituxan is a CD20-directed cytolytic antibody used, in combination with fludarabine and cyclophosphamide, for the treatment of patients with chronic lymphocytic leukemia (CLL). Rituxan is also used, in combination with Venclexta, for firstline treatment of CLL.

Genentech Oncology offers 2 financial assistance programs for patients using Rituxan:

Genentech Oncology Co-pay Assistance Program

The program ensures a $5 copay for Rituxan for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Rituxan free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Rituxan is also provided free for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Rituxan Hycela (rituximab/hyaluronidase human) Injection

Drug company: Genentech
866-422-2377

Rituxan Hycela is a combination of rituximab (a CD20- directed cytolytic antibody) and hyaluronidase human (an endoglycosidase) that is used, in combination with fludarabine and cyclophosphamide, for the treatment of untreated adults with chronic lymphocytic leukemia (CLL) and of previously treated CLL.

Genentech Oncology offers 2 financial assistance programs for patients using Rituxan Hycela:

Genentech Oncology Co-pay Assistance Program

Privately insured patients will pay only a $5 copay per prescription or infusion of Rituxan Hycela, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was refilled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Rituxan Hycela free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Rituxan Hycela is also provided free for patients who are unable to afford their outof- pocket costs and cannot find other financial assistance.

Venclexta (venetoclax) Tablets

Drug company: Abbvie/Genentech
866-422-2377

Venclexta is a BCL-2 inhibitor used for the treatment of patients with chronic lymphocytic leukemia (CLL), with or without 17p deletion, who have received at least 1 therapy. Venclexta is also used, in combination with Gazyva or with rituximab, for the first-line treatment of patients with CLL.

AbbVie and Genentech offer 2 financial assistance programs for patients using Venclexta:

Genentech Oncology Co-pay Assistance Program

The program ensures a $5 copay for Venclexta for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Venclexta free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Venclexta is also provided free for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Zydelig (idelalisib) Tablets

Drug company: Gilead
844-622-2377

Zydelig is a kinase inhibitor used, in combination with Rituxan, for the treatment of patients with relapsed chronic lymphocytic leukemia.

Zydelig AccessConnect offers 2 financial assistance programs for patients using Zydelig:

Zydelig AccessConnect Copay Coupon Card

Patients with private insurance and copays above $5 are eligible for this program. With the Copay Coupon Card, patients will pay only the first $5 per prescription fill of Zydelig. The maximum benefit allowed is 25% of the catalog price for a 12-month supply of Zydelig.

Zydelig AccessConnect Patient Assistance Program

Patients with no insurance or who have been denied coverage may be eligible to receive Zydelig free of charge through this program. Eligible patients must meet certain financial criteria.

Chronic Myeloid Leukemia (CML)

Bosulif (bosutinib)

Drug company: Pfizer
877-744-5675

Bosulif is a kinase inhibitor used for the treatment of adult patients with Ph+ chronic myeloid leukemia in the chronic, accelerated, or blast phase.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Bosulif:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Bosulif is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Bosulif for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Bosulif for free.

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia in chronic, blast crisis, or accelerated phase, or in chronic phase after the failure of interferon-alpha therapy.

Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Gleevec:

Novartis Oncology Universal Co-pay Program

Patients with private insurance will pay only $10 for a 30-day supply of Gleevec, with a maximum benefit of $10,630 per 30-day supply up to an annual maximum benefit of $30,000.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Gleevec for free until a prescription drug coverage becomes available to them.

Iclusig (ponatinib)

Drug company: Takeda Oncology
844-817-6468

Iclusig is a kinase inhibitor used for the treatment of adults with chronic-, accelerated-, or blast-phase chronic myeloid leukemia (CML). Iclusig is also used for adults with chronic-, accelerated-, or blast-phase CML with T315I mutation.

Takeda Oncology offers 2 financial assistance programs for patients using Iclusig:

Takeda Oncology Co-Pay Assistance Program

Eligible patients with private insurance will pay only a $10 per month copay or co-insurance for Iclusig. This program covers monthly out-of-pocket expenses of more than $10 per prescription, up to a maximum annual benefit of $25,000.

Takeda Oncology Patient Assistance Program

Through this program, eligible patients who are uninsured or underinsured may receive a monthly supply of Iclusig at no cost. Qualified patients may be enrolled in this program for up to 1 year.

Scemblix (asciminib) Tablets

Drug company: Novartis
800-245-5356

Scemblix is a kinase inhibitor used for the treatment of patients with chronic-phase Ph-positive chronic myeloid leukemia (CML), after 2 or more tyrosine kinase inhibitors, and for adults with chronic-phase Ph-positive CML and T315I mutation.

Novartis Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Scemblix:

Novartis Oncology Universal Co-pay Program

Patients with commercial or private insurance will pay the first $25 per prescription of Scemblix for an annual maximum benefit of $15,000.

Scemblix 30-Day Voucher

Through this program, patients with valid prescriptions can receive a free 30-day supply of Scemblix.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Scemblix for free until prescription drug coverage becomes available to them.

Sprycel (dasatinib)

Drug company: Bristol Myers Squibb
800-861-0048

Sprycel is a kinase inhibitor used for the treatment of patients with Ph+ chronic myeloid leukemia.

Bristol Myers Squibb Access Support offers 3 financial assistance programs for patients using Sprycel:

Co-Pay Assistance Program

Eligible patients may pay as little as $0 per 30-day supply of Sprycel, up to a maximum of $15,000 per calendar year.

Sprycel 30-Day Trial Offer

New patients may be eligible for a free 30-day trial offer of Sprycel.

Bristol Myers Squibb Patient Assistance Foundation

BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who are enrolled in Medicare Part D, or who do not have public or private insurance that helps pay for Sprycel, may be eligible for help paying for their prescription if they are receiving treatment as an outpatient and have an annual income up to 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.

Synribo (omacetaxine)

Drug company: Teva
888-587-3263

Synribo is used for the treatment of adults with chronic- or accelerated-phase chronic myeloid leukemia.

Teva offers 1 financial assistance program for patients using Synribo:

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Synribo for free.

Tasigna (nilotinib)

Drug company: Novartis
800-245-5356

Tasigna is a kinase inhibitor used for the treatment of patients older than 1 year with newly diagnosed chronic-phase Ph+ chronic myeloid leukemia (CML), or for patients older than 1 year with chronic-phase Ph+ CML that is resistant to previous tyrosine kinase inhibitor therapy. Tasigna is also used for adults with chronic-phase or accelerated-phase Ph+ CML that is resistant to or who are intolerant of Gleevec.

Novartis Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Tasigna:

Novartis Oncology Universal Co-Pay Program

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and co-insurance for Tasigna. The program pays the remaining balance until an annual maximum of $15,000 is met.

Tasigna 3 Months Free Trial Voucher

Eligible new patients can receive a free 3-month trial supply of Tasigna capsules.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients must be without insurance, be US citizens, and provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Tasigna for free until prescription drug coverage becomes available to them.

Hairy‑Cell Leukemia

Lumoxiti (moxetumomab pasudotox-tdfk)

Drug company: AstraZeneca
844-275-2360

Lumoxiti is a CD22-directed cytotoxin used for the treatment of adults with relapsed or refractory hairy-cell leukemia who have received at least 2 systemic therapies, including a purine nucleoside analog.

AstraZeneca Access 360 offers 1 financial assistance program for patients who have been prescribed Lumoxiti:

Access 360 Lumoxiti Patient Savings Program

Although the patient’s out-of-pocket costs may vary, this program aims for eligible patients to pay $0 per infusion of Lumoxiti, with a maximum annual savings of $26,000. Eligible patients must have private health insurance that partially covers the costs of Lumoxiti.

Mast‑Cell Leukemia

Ayvakit (avapritinib) Tablets

Drug company: Blueprint Medicines
888-258-7768

Ayvakit is a tyrosine kinase inhibitor used for the treatment of adults with advanced systemic mastocytosis, including patients with mast-cell leukemia.

Blueprint Medicines offers 5 financial assistance programs for patients who have been prescribed Ayvakit:

YourBlueprint Co-Pay Assistance Program

Eligible patients who have private or commercial insurance will pay as little as $0 per prescription of Ayvakit.

YourBlueprint Patient Assistance Program

Patients who are uninsured or who have limited insurance may be eligible to receive Ayvakit for free. Patients must reside in the United States and meet the financial eligibility criteria.

QuickStart Program

Patients may be eligible to receive a 15-day supply of medication at no cost through this program while waiting to get their insurance coverage.

Coverage Interruption Program

Patients who change their insurance or have a temporary interruption in their insurance coverage may be eligible to get a temporary supply of the medication at no cost.

Ayvakit Dose Exchange Program

Patients who had their dose of Ayvakit adjusted by their doctor can trade their remaining medication for the new dose at no cost.

Rydapt (midostaurin) Capsules

Drug company: Novartis
800-245-5356

Rydapt is a kinase inhibitor used for the treatment of adults with mast-cell leukemia.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Rydapt:

Novartis Oncology Universal Co-Pay Program

For eligible patients with private insurance, this copay program ensures a prescription copay of $10 per month for Rydapt. Novartis pays the remaining balance until the annual maximum of $15,000 is met.

Rydapt Now Access Program

For eligible patients with private insurance whose insurance coverage is delayed, this program provides a free 14-day supply of medication shipped directly to the patient’s home.

Novartis Patient Assistance Foundation

To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Rydapt for free until prescription drug coverage becomes available to them.

Table. Drugs Prescribed for Leukemia

Acute Lymphoblastic Leukemia (ALL)
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Besponsa (inotuzumab ozogamicin) for Injection
  • Drug company
  • Pfizer
  • Indications
  • Treatment of relapsed or refractory B-cell precursor ALL
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675




    Drug name (generic name)
  • Kymriah (tisagenlecleucel)
  • Drug company
  • Novartis
  • Indications
  • Treatment of B-cell precursor ALL in patients up to age 25
  • Patient support services
  • Kymriah Cares
    844-459-6742


    Drug name (generic name)
  • Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) Injection
  • Drug company
  • Jazz Pharmaceuticals
  • Indications
  • Treatment of ALL or lymphoblastic lymphoma in patients 1 month old or older who have hypersensitivity to E. coli-derived asparaginase
  • Patient support services
  • JazzCares Copay Savings Card
    833-533-5299

    JazzCares Patient Assistance Program
    833-533-5299


    Drug name (generic name)
  • Tecartus (brexucabtagene autoleucel)
  • Drug company
  • Kite Pharma
  • Indications
  • Treatment of adults with relapsed or refractory B-cell precursor ALL
  • Patient support services
  • Kite Konnect
    844-454-5483

Acute Myeloid Leukemia (AML)
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Idamycin PFS (idarubicin hydrochloride)
  • Drug company
  • Pfizer
  • Indications
  • Treatment of AML
  • Patient support services
  • Pfizer RxPathways
    866-706-2400


    Drug name (generic name)
  • Mylotarg (gemtuzumab ozogamicin) for Injection
  • Drug company
  • Pfizer
  • Indications
  • Treatment of CD33-positive AML in adults

    Treatment of relapsed or refractory CD33-positive AML in patients age 2 or older
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675

    Drug name (generic name)
  • Onureg (azacitidine) Tablets
  • Drug company
  • Bristol Myers Squibb
  • Indications
  • Treatment of patients with AML who achieved first complete remission or complete remission with incomplete blood count recovery after intensive induction chemotherapy and who cannot complete intensive curative therapy
  • Patient support services
  • BMS Oncology Co-Pay Assistance Program
    800-861-0048

    Bristol Myers Squibb Patient Assistance Foundation
    800-736-0003


    Drug name (generic name)
  • Tibsovo (ivosidenib) Tablets
  • Drug company
  • Servier Pharmaceuticals
  • Indications
  • First-line treatment of AML with IDH1 mutation in adults 75 or older or patients with comorbidities that preclude intensive chemotherapy

    Treatment of adults with relapsed or refractory AML with IDH1 mutation
  • Patient support services
  • Tibsovo Co-pay Program
    844-409-1141

    Patient Assistance Program
    844-409-1141

    QuickStart Program
    844-409-1141

    Coverage Interruption Program
    844-409-1141


    Drug name (generic name)
  • Vyxeos (daunorubicin + cytarabine) Liposome for Injection
  • Drug company
  • Jazz Pharmaceuticals
  • Indications
  • First-line treatment of therapy-related AML in adults and pediatric patients 1 year or older

    Treatment of AML with myelodysplasia-related changes
  • Patient support services
  • JazzCares Copay Savings Card
    833-533-5299

    JazzCares Patient Assistance Program
    833-533-5299


    Drug name (generic name)
  • Zarxio (filgrastim-sndz)
  • Drug company
  • Sandoz
  • Indications
  • Treatment of AML
  • Patient support services
  • Sandoz One Source Co-Pay Program
    844-726-3691

Chronic Lymphocytic Leukemia (CLL)
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Arzerra (ofatumumab)
  • Drug company
  • Novartis
  • Indications
  • Treatment of CLL, sometimes in combination with chlorambucil, or with fludarabine + cyclophosphamide
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254




    Drug name (generic name)
  • Gazyva (obinutuzumab)
  • Drug company
  • Genentech
  • Indications
  • First-line treatment of CLL, in combination with Imbruvica

    First-line treatment of CLL, in combination with Venclexta

    Treatment of CLL, in combination with chlorambucil
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Imbruvica (ibrutinib) Capsules/Tablets
  • Drug company
  • Pharmacyclics
  • Indications
  • First-line treatment of CLL, with or without 17p deletion

    First-line treatment of CLL, in combination with Gazyva
  • Patient support services
  • Imbruvica Copay Card
    888-968-7743

    Johnson & Johnson Patient Assistance Foundation
    800-652-6227



    Drug name (generic name)
  • Venclexta (venetoclax) Tablets
  • Drug company
  • AbbVie/Genentech
  • Indications
  • Treatment of CLL with or without 17p deletion, after 1 therapy

    First-line treatment of CLL, in combination with Gazyva or with rituximab
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331


Chronic Myeloid Leukemia (CML)
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services








Hairy‑Cell Leukemia
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Lumoxiti (moxetumomab pasudotox-tdfk)
  • Drug company
  • AstraZeneca
  • Indications
  • Treatment of relapsed or refractory hairy-cell leukemia after systemic therapy
  • Patient support services
  • Access 360 Lumoxiti Patient Savings Program
    844-275-2360

Mast‑Cell Leukemia
  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services


Share this:

Last modified: March 17, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest